Actively Recruiting
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Led by City of Hope Medical Center · Updated on 2025-07-11
150
Participants Needed
1
Research Sites
1150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
CONDITIONS
Official Title
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who had histologically confirmed esophageal squamous cell carcinoma.
- Patients who had undergone chemotherapy.
- Patients receiving initial chemotherapy
- Written informed consent following full study information is provided to the patient.
You will not qualify if you...
- Patients for whom a preoperative biopsy sample cannot be obtained
- Patients who cannot assess at 2 months later after chemotherapy.
- Patients with multiple cancers.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yamanashi Universiy
Chūō, Yamanashi, Japan, 4093898
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
K
Koichi Takiguchi, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here